Avacincaptad Pegol and Anti-VEGF in Real-World Practice

Clinical Report: Avacincaptad Pegol and Anti-VEGF in Real-World Practice

Overview

An analysis of the IRIS Registry revealed that concomitant anti-VEGF therapy did not significantly impact the treatment patterns of avacincaptad pegol in patients with geographic atrophy. The study included over 13,000 eyes and highlighted similar injection frequencies and intervals between groups receiving and not receiving anti-VEGF.

Background

Neovascular age-related macular degeneration (nAMD) and choroidal neovascularization (CNV) are leading causes of vision loss, making effective treatment strategies essential. Anti-VEGF therapies are standard care, yet real-world outcomes may differ from clinical trials. Understanding the interaction between avacincaptad pegol and anti-VEGF therapies is crucial for optimizing patient management.

Data Highlights

Parameter	Concomitant Anti-VEGF	No Anti-VEGF
Mean Injections	3.9	3.6
Mean Interval (weeks)	7.2	6.9
Discontinuation Rate	10.8%	6.7%
Treatment-Emergent Adverse Events	3.8%	2.6%

Key Findings

34.3% of patients had nAMD and 28.2% had CNV at baseline.
22.7% of eyes received concomitant anti-VEGF therapy during follow-up.
Discontinuation rates were higher in eyes receiving anti-VEGF (10.8%) compared to those not receiving it (6.7%).
Common adverse events included CNV and nAMD, with severe vision loss occurring in 0.07% to 0.18% of eyes.
Switching to pegcetacoplan was uncommon, at 2.5% and 3.4% for the respective groups.

Clinical Implications

The findings suggest that avacincaptad pegol can be administered alongside anti-VEGF therapy without significant alterations in treatment patterns. Clinicians should be aware of the similar safety profiles and injection frequencies when considering combination therapy.

Conclusion

Concomitant anti-VEGF therapy did not meaningfully affect avacincaptad pegol treatment patterns, indicating its potential for use in a real-world setting without compromising safety.